Owen David R, Wood David M, Archer John R H, Dargan Paul I
Division of Brain Sciences, Imperial College London, London, UK.
Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust and King's Health Partners, London, UK.
Drug Alcohol Rev. 2016 Sep;35(5):591-6. doi: 10.1111/dar.12356. Epub 2015 Dec 23.
There has been a global increase in the availability and use of novel psychoactive substances (NPS) over the last decade. Phenibut (β-phenyl-γ-aminobutyric acid) is a GABAB agonist that is used as an NPS. Here, we bring together published scientific and grey information sources to further understand the prevalence of use, desired effects and acute toxicity of phenibut.
Using European Monitoring Centre for Drugs and Drug Addiction Internet snapshot methodology, we undertook an English language Internet snapshot survey in May 2015 to gather information on the availability and price of phenibut from Internet NPS retailers. To gather information on prevalence of use, desired effects and/or adverse effects, we searched grey literature (online drug discussion forums) and medical literature (PubMed and abstracts from selected International Toxicology conferences).
We found 48 unrelated Internet suppliers selling phenibut in amounts ranging from 5 g (US$1.60, £1.01/g) to 1000 kg (US$0.23, £0.14/g). Capsules containing 200-500 mg of phenibut were available in packs of between 6 (US$4.45, £2.80/g) and 360 (US$0.43, £0.27/g). According to the grey literature, phenibut is taken for its anxiolytic and euphoric properties, with tolerance and withdrawal syndromes commonly reported adverse effects. Phenibut is taken orally at an average dose of 2.4 g. Case reports in the medical literature feature users who present to emergency departments heavily sedated or experiencing withdrawal. There have been no reported deaths relating to phenibut use.
Phenibut is readily available in the UK from Internet sites selling NPS. Its desired and adverse effects appear similar to other gamma-aminobutyric acid receptor agonists. [Owen DR, Wood DM, Archer JRH, Dargan PI. Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity. Drug Alcohol Rev 2016;35:591-596].
在过去十年中,新型精神活性物质(NPS)的可得性和使用在全球范围内有所增加。苯乙胺(β-苯基-γ-氨基丁酸)是一种用作新型精神活性物质的GABAB激动剂。在此,我们汇集已发表的科学信息源和灰色信息源,以进一步了解苯乙胺的使用流行情况、预期效果和急性毒性。
我们采用欧洲药物和药物成瘾监测中心的互联网快照方法,于2015年5月开展了一项英语互联网快照调查,以收集来自互联网新型精神活性物质零售商的苯乙胺可得性和价格信息。为收集使用流行情况、预期效果和/或不良反应的信息,我们检索了灰色文献(在线药物讨论论坛)和医学文献(PubMed以及选定国际毒理学会议的摘要)。
我们发现有48家不相关的互联网供应商销售苯乙胺,销售数量从5克(1.60美元,1.01英镑/克)到1000千克(0.23美元,0.14英镑/克)不等。含有200 - 500毫克苯乙胺的胶囊,每包6粒(4.45美元,2.80英镑/克)至360粒(0.43美元,0.27英镑/克)不等。根据灰色文献,服用苯乙胺是因其具有抗焦虑和欣快特性,耐受性和戒断综合征是常见的不良反应。苯乙胺的平均口服剂量为2.4克。医学文献中的病例报告描述了就诊于急诊科的使用者,他们处于深度镇静状态或正在经历戒断反应。尚未有与使用苯乙胺相关的死亡报告。
在英国,从销售新型精神活性物质的网站很容易获得苯乙胺。其预期效果和不良反应似乎与其他γ-氨基丁酸受体激动剂相似。[欧文·DR、伍德·DM、阿彻·JRH、达根·PI。苯乙胺(4-氨基-3-苯基丁酸):可得性、使用流行情况、预期效果和急性毒性。《药物与酒精评论》2016年;35:591 - 596]